Performance guarenteed

# CD44var (v6) Monoclonal Antibody (VFF-18), eBioscience™

### **Product Details**

Size	100 µg
Species Reactivity	Human
Published Species	Hamster, Human
Host/Isotype	Mouse / IgG1
Class	Monoclonal
Туре	Antibody
Clone	VFF-18
Conjugate	Unconjugated
Immunogen	Rec. Human CD44var (v6)
Form	Liquid
Concentration	1 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS
Contains	no preservative
Storage conditions	-20°C
RRID	AB_10596813

Applications	Tested Dilution	Publications
Western Blot (WB)	Assay-Dependent	3 Publications
Immunohistochemistry (IHC)	-	6 Publications
Immunohistochemistry (Paraffin) (IHC (P))	Assay-Dependent	-
Immunocytochemistry (ICC/IF)	-	1 Publication
Flow Cytometry (Flow)	Assay-Dependent	2 Publications

#### **Product Specific Information**

Description: Specifically recognizes an epitope encoded by exon v6 on the variant portion of human CD44.

Standard CD44 (CD44s) lacks the entire variable region and is found mainly in cells of lymphohematopoietic origin. The multiple isoforms (designated CD44v; v = variant) contain alternatively spliced exons inserted within the extracellular domain. These isoforms are known as CD44v1, CD44v2, CD44v3, CD44v4, CD44v5, CD44v6, CD44v7, CD44v8, CD44v9, CD44v10, CD44v11.

Applications Tested: Flow Cytometry, Immunohistochemistry (Paraffin), Western Blotting.

Purity: >95%.

1

## **□ 12 References**

## Western Blot (3)

JCI insight	Year
PDX-derived organoids model in vivo drug response and secrete	2020
biomarkers.	Species
"Published figure using CD44var (v6) monoclonal antibody (Product # BMS125) in Western Blot"	Human
Authors: Huang L,Bockorny B,Paul I,Akshinthala D,Frappart PO,Gandarilla O,Bose A,Sanchez-Gonzalez V,Rouse EE, Lehoux SD,Pandell N,Lim CM,Clohessy JG,Grossman J,Gonzalez R,Del Pino SP,Daaboul G,Sawhney MS,Freedman SD,Kleger A,Cummings RD,Emili A,Muthuswamy LB,Hidalgo M,Muthuswamy SK	
Dncology reports	Year
CD44 alternative splicing and hnRNP A1 expression are associated with	2015
he metastasis of breast cancer.	Species
BMS125 was used in Western Blotting to study the effects of the knockdown of hnRNP A1 on the splicing of CD44 in reast cancer cells."	Human
Authors: Loh TJ,Moon H,Cho S,Jang H,Liu YC,Tai H,Jung DW,Williams DR,Kim HR,Shin MG,Liao DJ,Zhou J,Shi W, Zheng X,Shen H	
	view more WB references on thermofishe
nmunohistochemistry (6) Breast cancer research and treatment	/iew more WB references on thermofishe
nmunohistochemistry (6) Breast cancer research and treatment	
amunohistochemistry (6) Breast cancer research and treatment A randomized, placebo-controlled phase 2 study of paclitaxel in	Year
nmunohistochemistry (6) Breast cancer research and treatment A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line	<b>Year</b> 2021
nmunohistochemistry (6)	Year 2021 Species
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). BMS125 was used in Immunohistochemistry to report the results of a phase 2 randomized, double-blind study [fRida rial (NCT02370238)] evaluating the safety and efficacy of reparixin plus paclitaxel vs. placebo plus paclitaxel in untreated metastatic triple-negative breast cancer."	Year 2021 Species Human Dilution
A randomized, placebo-controlled phase 2 study of paclitaxel in Combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). BMS125 was used in Immunohistochemistry to report the results of a phase 2 randomized, double-blind study [fRida rial (NCT02370238)] evaluating the safety and efficacy of reparixin plus paclitaxel vs. placebo plus paclitaxel in untreated metastatic triple-negative breast cancer." Authors: Goldstein LJ,Mansutti M,Levy C,Chang JC,Henry S,Fernandez-Perez I,Prausovà J,Staroslawska E,Viale G, But F,B,McCanna S,Ruffini PA,Wicha MS,Schott AF	Year 2021 Species Human Dilution 1:250 Year
Arandomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line cherapy for metastatic triple-negative breast cancer (fRida). BMS125 was used in Immunohistochemistry to report the results of a phase 2 randomized, double-blind study [fRida rial (NCT02370238)] evaluating the safety and efficacy of reparixin plus paclitaxel vs. placebo plus paclitaxel in intreated metastatic triple-negative breast cancer." Authors: Goldstein LJ,Mansutti M,Levy C,Chang JC,Henry S,Fernandez-Perez I,Prausovà J,Staroslawska E,Viale G, Butler B,McCanna S,Ruffini PA,Wicha MS,Schott AF	Year 2021 Species Human Dilution 1:250
Arandomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). BMS125 was used in Immunohistochemistry to report the results of a phase 2 randomized, double-blind study [fRida rial (NCT02370238)] evaluating the safety and efficacy of reparixin plus paclitaxel vs. placebo plus paclitaxel in Intreated metastatic triple-negative breast cancer." Authors: Goldstein LJ,Mansutti M,Levy C,Chang JC,Henry S,Fernandez-Perez I,Prausovà J,Staroslawska E,Viale G, Butter B,McCanna S,Ruffini PA,Wicha MS,Schott AF Dincogene Stem cell CD44v isoforms promote intestinal cancer formation in Apc	Year 2021 Species Human Dilution 1:250 Year 2014 Species
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).	Year 2021 Species Human Dilution 1:250 Year 2014

View more IHC references on thermofisher.com

## More applications with references on thermofisher.com

ICC/IF (1) Flow (2)

ST

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. No OTHER WARRANTES, EXPRESS OR IMPLED, ARRANTES DE REFOREMANTES OF MERCHANTABILITY. TINTESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR THE RODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (III) MISUES, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HADDLING OF THE PRODUCTS. NOt Not unematation accompanying the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.

2